GHRP-6 — Research Overview
Chemical Name: Growth Hormone-Releasing Peptide-6 (GHRP-6) Amino Acid Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 Structure: Synthetic hexapeptide analog of met-enkephalin. Contains two D-amino acids (D-Trp at position 2 and D-Phe at position 5) conferring proteolytic resistance and receptor binding affinity. Molecular Formula: C46H56N12O6 Molecular Weight: 873.0 daltons Historical Significance: GHRP-6 was the first synthetic GH secretagogue identified, discovered by Cyril Y. Bowers and colleagues at Tulane University in 1984 through systematic modification of met-enkephalin analogs. Its characterization preceded the identification of the GHS-R1a receptor (1996) and the discovery of ghrelin (1999) — the endogenous hormone that was subsequently identified as the natural ligand for the receptor GHRP-6 had been pharmacologically targeting for over a decade. Every subsequent GH secretagogue — GHRP-2, hexarelin, ipamorelin, MK-677 — traces its scientific lineage to the GHRP-6 discovery. WADA Status: Prohibited substance under S2 (peptide hormones, growth factors, related substances, and mimetics) Regulatory Status: Not approved by the FDA or any major regulatory authority for therapeutic use. No regulatory approval in any jurisdiction — distinguishing it from GHRP-2 which holds Japanese diagnostic approval. Category: Original synthetic GHS-R1a agonist / ghrelin mimetic / growth hormone secretagogue / cytoprotective and cardioprotective research peptide
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is GHRP-6?
GHRP-6 is the foundational compound of the GHRP (Growth Hormone-Releasing Peptide) family — the first synthetic GH secretagogue ever characterized, developed by American endocrinologist Cyril Y. Bowers and colleagues at Tulane University and published in Endocrinology in 1984. Its discovery arose from the systematic observation that certain chemical modifications of the endogenous opioid peptide met-enkephalin produced unexpected, dose-dependent growth hormone release from pituitary cells through a mechanism entirely distinct from GHRH. This was a landmark finding because it demonstrated the existence of a second, independent pathway for GH secretion at the pituitary level — one that bypassed the classical GHRH/somatostatin regulatory system.
The scientific impact of GHRP-6 extended well beyond its own pharmacological properties. The search for the endogenous ligand that activated the receptor GHRP-6 was discovered to target led directly to the identification of the GHS-R1a receptor in 1996 and, three years later in 1999, to the discovery of ghrelin — the stomach-derived hormone that is now understood as the principal physiological regulator of pre-meal hunger and GH pulsatility. GHRP-6 is pharmacologically a synthetic ghrelin mimetic, though it was developed more than a decade before ghrelin was known to exist.
GHRP-6’s defining pharmacological characteristic within the GHRP class is its pronounced appetite stimulation — the strongest among all characterized GHRP family members. This appetite effect operates through GHS-R1a activation in the hypothalamic arcuate nucleus, driving NPY/AgRP orexigenic neuron activation in a manner that closely mimics the pre-meal ghrelin surge that signals hunger. This property simultaneously makes GHRP-6 a research liability for GH axis studies where appetite confounds results, and a research asset for cachexia, wasting, and appetite regulation studies where orexigenic activity is the endpoint of interest.
Beyond its role as a GH secretagogue, GHRP-6 has been identified as a compound with broad cytoprotective and cardioprotective properties that operate through two distinct receptors — GHS-R1a and CD36 — through mechanisms partially independent of GH release. This second pharmacological dimension has become an increasingly active research area.
Dual Receptor Biology — A Key Distinguishing Feature
Unlike most peptides studied in this catalog which interact with a single characterized receptor, GHRP-6 has been demonstrated to bind two pharmacologically relevant receptors:
GHS-R1a (Growth Hormone Secretagogue Receptor 1a): The primary target mediating GH release, appetite stimulation, gastric motility effects, and much of the cytoprotective activity. GHS-R1a is expressed in the anterior pituitary, hypothalamus, and multiple peripheral tissues including the heart, gastrointestinal tract, and immune cells.
CD36 (Cluster of Differentiation 36): A scavenger receptor expressed abundantly in the cardiovascular system, adipose tissue, and cutaneous wound granulation tissue. CD36 binding by GHRP-6 mediates specific cytoprotective effects — particularly the anti-fibrotic, anti-inflammatory, and wound healing properties — through signaling mechanisms distinct from GHS-R1a pathways. The discovery of CD36 as a second GHRP receptor significantly expanded the mechanistic understanding of GHRP-6’s broad biological activity and explained observed effects in tissues with low or absent GHS-R1a expression.
Mechanism of Action
GHS-R1a-mediated GH release: GHRP-6 binding to GHS-R1a activates phospholipase C (PLC) through Gq protein coupling, generating diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 triggers calcium release from intracellular stores and DAG activates protein kinase C (PKC). This calcium-dependent, cAMP-independent signaling cascade drives GH vesicle exocytosis from pituitary somatotrophs — a mechanistic profile confirmed by published studies in human pituitary somatotrophinoma cells demonstrating dose-dependent phosphatidylinositol turnover stimulation by GHRP-6.
Dual hypothalamic action: GHRP-6 acts both directly on pituitary somatotrophs and indirectly through hypothalamic pathways — stimulating GHRH-producing arcuate nucleus neurons and suppressing somatostatin tone from the periventricular nucleus. Human pharmacology studies established this dual action by demonstrating that GHRP-6-induced GH release is almost completely abolished in patients with hypothalamopituitary disconnection, confirming that intact hypothalamic signaling is required for most of GHRP-6’s in vivo GH-releasing effect.
GHRH synergy: GHRP-6 and GHRH activate complementary intracellular signaling pathways (PLC/calcium versus cAMP/PKA) on pituitary somatotrophs, producing synergistic GH responses that substantially exceed the sum of individual responses from each compound alone. Published human data confirmed that GH secretion following GHRH+GHRP-6 was significantly higher than the arithmetic sum of both compounds administered separately (P less than 0.05), establishing true pharmacological synergy rather than simple additivity.
Appetite stimulation: GHS-R1a activation in the arcuate nucleus stimulates NPY (neuropeptide Y) and AgRP (agouti-related peptide) neurons — the primary orexigenic pathway in the hypothalamus — producing a compelling hunger drive that begins 20 to 30 minutes post-administration and lasts 30 to 60 minutes. GHRP-6 produces more robust arcuate NPY/AgRP activation than GHRP-2 or ipamorelin at equivalent GH-releasing doses, making it the most orexigenic member of the GHRP class.
Gastric motility: GHS-R1a expressed on vagal nerve afferents and directly in the gastrointestinal tract is activated by GHRP-6, promoting gastric emptying and GI motility — contributing additively to the appetite-stimulating effect through peripheral hunger signaling to the brainstem.
CD36-mediated cytoprotective effects: GHRP-6 binding to CD36 in the cardiovascular system and wound tissue activates prosurvival signaling through PI3K/Akt pathways, upregulates PPARgamma (which drives anti-fibrotic gene expression), suppresses NFkB activation (reducing pro-inflammatory cytokine production), and triggers anti-apoptotic cascades. These CD36-mediated effects are partially independent of GHS-R1a and GH axis function, explaining GHRP-6’s cytoprotective properties in tissues where GHS-R1a expression is low.
Cardiomyocyte effects — positive inotropic: GHRP-6 produces a positive inotropic effect in cardiac muscle (increased contractile force without increased heart rate) through GHS-R1a-mediated elevation of Ca2+ influx via PLC/DAG/PKC signaling through voltage-gated calcium channels and calcium release from intracellular stores.
HPA axis effects: Like GHRP-2, GHRP-6 elevates ACTH and cortisol at GH-releasing doses, particularly at higher doses. This effect is dose-dependent and is mediated through hypothalamic CRF/AVP pathways rather than direct pituitary corticotroph stimulation.
Published Research
Study 1 — Foundational Discovery: GHRP-6 as the First Synthetic GH Secretagogue
Authors: Bowers CY, Momany FA, Reynolds GA, Hong A Year: 1984 Journal: Endocrinology Referenced via: Bowers CY et al. Endocrinology 1984;114:1537-1545
This landmark 1984 publication by Bowers and colleagues at Tulane University was the first characterization of GHRP-6 as a synthetic hexapeptide that specifically and dose-dependently released growth hormone both in vitro from pituitary cells and in vivo — through a mechanism entirely distinct from GHRH.
GHRP-6 was the most potent compound in a systematic series of met-enkephalin analogs and elicited GH release that was completely independent of the cAMP second messenger system used by GHRH, establishing from the outset that a second, independent pathway for GH secretion existed.
The structural requirements for GH-releasing activity were characterized, including the importance of D-amino acid substitutions at positions 2 and 5 for proteolytic resistance and receptor binding.
This publication initiated the entire GH secretagogue research field and ultimately led to the identification of GHS-R1a in 1996 and ghrelin in 1999 — positioning GHRP-6 as the founding compound of one of the most influential research programs in neuroendocrinology over the subsequent four decades.
Study 2 — First Human Clinical Data: GHRP-6 Stimulates GH and Acts Synergistically with GHRH
Authors: Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO Year: 1990 Journal: Journal of Clinical Endocrinology and Metabolism PMID referenced via published literature
This was the first published demonstration that GHRP-6 stimulates GH release in normal human volunteers and acts synergistically with GHRH — directly translating the 1984 in vitro and animal findings into human pharmacology and establishing the foundational clinical data for the entire GHRP class.
GHRP-6 administered to normal volunteers produced significant GH release through a mechanism distinct from GHRH, confirming that the novel receptor pathway characterized in animal models was functionally active in the human pituitary.
The combination of GHRP-6 and GHRH produced synergistic GH responses significantly exceeding the sum of individual responses — establishing the dual-receptor synergy principle that has since been validated across the entire GHRP class and forms the pharmacological rationale for combining GHRPs with GHRH analogs.
This study established GHRP-6 as the prototype human GH secretagogue, initiating decades of subsequent human clinical research across the GHRP class.
Study 3 — Mechanism Established: GHRP-6 Hypothalamic Action and Synergy Confirmed in Human Subjects
Authors: Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF Year: 1995 Journal: Journal of Clinical Endocrinology and Metabolism PMID: 7883854 Full text: https://pubmed.ncbi.nlm.nih.gov/7883854/
This study in 12 patients with hypothalamopituitary disconnection and 11 normal controls directly established that GHRP-6’s primary action requires an intact hypothalamic-pituitary connection — characterizing the site of action as predominantly hypothalamic rather than purely pituitary.
In normal subjects, GH secretion (area under the curve) was 483.7 after GHRH, 1434.8 after GHRP-6, and 3771.5 after GHRH plus GHRP-6 — with the combined response significantly higher than the arithmetic sum of individual responses, confirming genuine synergy.
In patients with hypothalamopituitary disconnection, GHRP-6 alone produced almost complete blockade of GH secretion (97.3 versus 1434.8 in controls, P less than 0.01), while GHRH alone maintained near-normal responses — directly demonstrating that GHRP-6’s in vivo GH-releasing activity depends critically on intact hypothalamic inputs.
The synergistic action of GHRH+GHRP-6 was abolished in patients with disconnection, further confirming that GHRP-6’s ability to amplify GHRH-induced GH release requires hypothalamic participation.
The authors concluded that GHRP-6 exerts its main action at the hypothalamic level, providing indirect evidence that it acts by stimulating GHRH release and/or suppressing somatostatin tone rather than acting exclusively on pituitary somatotrophs.
Study 4 — GHRP-6 Wound Healing: CD36 as Active Receptor in Cutaneous Wound Granulation Tissue
Authors: Berlanga-Acosta J et al. Year: 2016 Journal: Frontiers in Pharmacology (PMC) PMID: 27200188 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4854984/
This study examined GHRP-6’s effects on cutaneous wound healing and hypertrophic scar formation through CD36 receptor biology — establishing wound granulation tissue as a pharmacologically active target for GHRP-6’s second receptor system.
Full-thickness excisional wounds (6mm diameter) were created in Wistar rats and treated topically twice daily with GHRP-6 at 400 micrograms/mL for 5 days. The rabbit ear hypertrophic scar model was implemented with daily GHRP-6 treatment for 30 days.
GHRP-6 accelerated wound closure — differences in wound area reduction appeared within the first 24 hours of post-injury treatment and remained stable through hour 96.
GHRP-6 pharmacodynamics involved attenuation of immunoinflammatory mediators, their effector cells, and reduced expression of profibrogenic cytokines — with RT-PCR analysis confirming suppression of TGF-beta, CTGF, and PDGF expression consistent with PPARgamma upregulation.
In the hypertrophic scar rabbit model, GHRP-6 dramatically reduced the onset of exuberant scars without the adverse effects associated with first-line treatment triamcinolone acetonide. However GHRP-6 showed no effect on reversal of consolidated established lesions.
CD36 was confirmed to be abundantly represented in cutaneous wound granulation tissue — establishing mechanistic relevance of the second GHRP-6 receptor in this tissue context. The authors concluded that CD36 is an active and pharmacologically approachable receptor for attenuating wound inflammation and accelerating closure.
Study 5 — Cardioprotection: GHRP-6 Prevents Doxorubicin-Induced Myocardial and Extramyocardial Damage
Authors: Published in Frontiers in Pharmacology Year: 2024 Journal: Frontiers in Pharmacology Full text: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1402138/full
This study examined whether GHRP-6 could prevent the onset of dilated cardiomyopathy and heart failure and multi-organ damage induced by doxorubicin — the leading cardiotoxic chemotherapy agent — in otherwise healthy rats evaluated by serial transthoracic echocardiography.
GHRP-6 administration concomitant with doxorubicin attenuated cardiac and extracardiac toxicity, reducing animals’ morbidity and mortality compared to doxorubicin-alone controls.
Cardioprotective effects included attenuation of pro-oxidant activity, enhanced antioxidant reserves, protection of mitochondrial ultrastructure, and upregulation of the anti-apoptotic gene Bcl-2 in treated animals.
The cytoprotective effects extended beyond the myocardium to include hepatocytes, renal tubular cells, bronchial epithelia, and intestinal enterocytes — demonstrating systemic multi-organ protection consistent with GHRP-6’s broad cytoprotective pharmacological profile.
These effects are mediated at least partly through CD36 receptor binding independent of the GHS-R1a/GH pathway, reflecting the dual receptor biology unique to the GHRP class.
Study 6 — Cytoprotective Review: Historical Evidence for GHRP Cardioprotection and Cytoprotection
Authors: Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D et al. Year: 2017 Journal: Clinical Medicine Insights: Cardiology (PMC) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC5392015/
This comprehensive peer-reviewed review synthesized decades of published evidence for GHRP class cardioprotective and cytoprotective properties, with GHRP-6 as the primary compound of focus.
GHRP-6 and the GHRP class bind two receptors — GHS-R1a and CD36 — which redundantly or independently exert relevant biological effects on cell survival, cardiac function, and tissue protection.
The characterized cardioprotective mechanisms of GHRP-6 include: positive inotropic effects mediated by calcium influx through PLC/DAG/PKC pathways; anti-fibrotic effects through PPARgamma upregulation and TGF-beta/CTGF/PDGF downregulation; anti-inflammatory effects through NFkB suppression; and cell survival promotion through the PI3K/Akt pathway and HIF-1alpha induction.
Evidence from multiple experimental scenarios including ischemia/reperfusion, doxorubicin cardiotoxicity, and dilated cardiomyopathy models consistently showed GHRP-6 as an antinecrogenic and antiapoptotic agent with broad cytoprotective properties.
The authors note that despite intense basic pharmacological research, alternatives to prevent cell and tissue demise before lethal insults remain an empty niche in the clinical armamentarium — positioning GHRP-6 as one of the most promising cytoprotective candidates awaiting clinical translation.
GHRP-6 in the GHRP Class: Comparative Profile
GHRP-6 occupies the foundational position in the GHRP class as the compound from which all others were derived. Its specific comparative profile:
Versus GHRP-2: GHRP-2 is more potent per unit dose for GH release. GHRP-6 produces stronger appetite stimulation. GHRP-2 holds Japanese regulatory approval for diagnostic use. Both produce comparable ACTH/cortisol elevation.
Versus ipamorelin: Ipamorelin is a third-generation selective GHS-R1a agonist that does not elevate cortisol, ACTH, or prolactin at GH-releasing doses and produces minimal appetite stimulation. For experiments where clean GH axis stimulation without appetite or HPA confounders is required, ipamorelin is preferred. GHRP-6 is preferred when appetite stimulation, orexigenic biology, or the full multi-hormone profile of GHS-R1a agonism is the research focus.
Versus hexarelin: Hexarelin is the most acutely potent GH releaser in the class but produces the most pronounced cortisol, ACTH, and prolactin elevation and shows the most rapid tachyphylaxis with repeated dosing. GHRP-6 is generally more suitable for sustained research protocols.
Versus GHRH: Combined GHRP-6+GHRH consistently produces synergistic GH responses 3 to 5-fold greater than either compound alone, reflecting complementary receptor signaling pathways.
An Honest Research Note on Appetite Stimulation
GHRP-6’s appetite stimulation is its most clinically significant distinguishing feature from other GHRPs and must be considered in any research protocol design. The appetite effect begins 20 to 30 minutes after administration and can be substantial. For research investigating GH axis pharmacology where appetite stimulation is an unwanted confounder, ipamorelin is a more appropriate research tool. For research specifically investigating GHS-R1a-mediated appetite and energy homeostasis, GHRP-6’s potent orexigenic activity is itself the research asset. In cachexia and wasting condition research, the appetite-stimulating property represents a potential therapeutic research direction independent of GH axis effects.
Current Research Status
GHRP-6 is not approved by the FDA or any major regulatory authority for any therapeutic indication. It is classified as a WADA prohibited substance. Research continues actively in the areas of cardioprotection and cytoprotection, wound healing and scar prevention, appetite and energy homeostasis through GHS-R1a biology, and multi-organ protection in chemotherapy toxicity models. No Phase 3 human clinical trials for therapeutic applications of GHRP-6 have been published.
Reconstitution Note
GHRP-6 is a synthetic peptide. Bacteriostatic water is the standard reconstitution solvent. GHRP-6 dissolves readily in bacteriostatic water without requiring acidic solvents. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the GHRP-6 product page: https://roguecompounds.com/product/ghrp-6/